Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 29, 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to share acquisition prices:
- Ordinary Share Price: 1,502.00 pence
- ADS Price: $42.64
Material Changes
The document details the acquisition of Ordinary Shares and American Depositary Shares (ADSs) by specific directors and PDMRs. These acquisitions resulted from the re-investment of dividends paid to shareholders on April 14, 2016, under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan. The transactions include both personal contribution elements and matching elements (GSK contribution).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of insider share transactions.
Key Facts for Investor Verification
- Transaction Type: Dividend re-investment under the 2009 Deferred Annual Bonus Plan.
- Participants: Includes Sir Andrew Witty, Dr. M. M. Slaoui, and other named directors/PDMRs.
- Allocation Date: GSK was advised of these allocations on April 28, 2016.
- Share Counts: Specific fractional share and ADS counts were acquired by each individual, with matching contributions equal to personal contributions for all listed participants.